Article
Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Frontiers in immunology - 1 Jan 2023
Chen Dongna, Li Lin, Wang Mingzhao, Hu Xingsheng, Jiang Jun, Li Weihua, Yang Lin, Fan Meng, Shi Yuankai, Lv Fang, Liu Yutao
Abstract excerpt
Objective: This study sought to assess the efficacy and safety of immunotherapy combined with single-agent chemotherapy as a second- or later-line setting for metastatic non-small cell lung cancer (NSCLC) and to provide clinical evidence for this treatment regimen. The predictive value of extracellular vesicle (EV) membrane proteins was explored in patients who underwent this treatment. Methods: Clinical data...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.